-
2026-08-13
GenSci's Ophthalmology Pipeline: IND Approval Secured for Three IndicationsLearn More
-
2026-07-31
GenSci144, a Novel SLC6A19 Inhibitor, Receives IND Approval from NMPALearn More
-
2026-07-30
Gensci's VEGFR2 mAb NDA Accepted by NMPALearn More
-
2026-07-30
GenSci098 Receives FDA Fast Track Designation and Advances into Phase 2 Clinical TrialsLearn More
-
2024-08-21
Jintrolong® New Dosage Form of Long-acting Somatropin Injection ApprovedLearn More
-
2024-08-06
Clinical Trial Commencement of GenSci098 Injection ApprovedPreclinical data indicate GenSci098 has the potential to become a new treatment for Thyroid Eye Disease
Learn More
-
2024-07-26
Zhejiang University – GenSci Joint Research Center of Children’s Health establishedLearn More
-
2024-07-23
NMPA: New Drug Application of Recombinant Human Follicle-Stimulating Hormone - CTP Fusion Protein Injection AcceptedThis product will potentially enhance convenience and patient compliance
Learn More
-
2024-07-09
R&D Innovation Accelerator: Shanghai Children's Hospital and GenSci Ink Strategic Cooperation AgreementTwo Sides will Collaboratively Set Up a R&D Center
Learn More
-
2024-07-03
GenSci Invites you to join us in CPHI South East Asia 2024Join us at Booth H23 from July 10 to 12, 2024 to explore GenSci's flagship products.
Learn More